Background: Bortezomib is an inhibitor of proteasome and NF-κB, with activity in various
solid tumors and hematological malignancies. Aim: The aim of the study was the analysis of …

Prognosis of childhood acute lymphoblastic leukemia (ALL) has been dramatically
improved. However, prognosis of the cases refractory to primary therapy is still poor. Recent …

VELCADE®(bortezomib, Millennium Pharmaceuticals, Inc., Cambridge, MA, and Johnson &
Johnson Pharmaceutical Research & Development, LLC, Raritan, NJ) is a first-in-class …

Purpose We evaluated the expression of proteasome subunits to assess whether the
proteasome could be a therapeutic target in cisplatin-resistant lung cancer cells. Methods …

The cellular and molecular effects of the proteasome inhibitor bortezomib on breast cancer
cells are as yet poorly characterized. Here, in a panel of six breast cancer cell lines …

Multi-drug resistance (MDR) is one of the obstacles for leukemia therapy, the major cause is
an overexpression of P-glycoprotein (P-gp) leading to increased drug efflux. We investigated …

The proteasome plays a pivotal role in controlling cell proliferation, apoptosis, and
differentiation in a variety of tumor cells. Bortezomib is a boronic acid dipeptide derivative …

The proteasome is a multicatalytic threonine protease responsible for intracellular protein
turnover in eukaryotic cells, including the processing and degradation of several proteins …

Abstract Bortezomib (Velcade, formerly PS-341) is proteasome inhibitor with documented
antitumor activity in multiple myeloma and other lymphoid malignancies. We performed a …

The development of proteasome inhibitors (PIs) has transformed the treatment of multiple
myeloma and mantle cell lymphoma. To date, two PIs have been FDA approved, the …